SAN DIEGO, CA -- (Marketwired) -- 12/17/14 -- Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cell-based virology assays and molecular diagnostic systems, announced today that it has received 510(k) marketing clearance and CLIA waiver by the United States Food and Drug Administration (FDA) for its Sofia Strep A+ Fluorescent Immunoassay (FIA) for the rapid detection of infections by Group A Streptococcus bacteria. These bacteria are the most common cause of bacterial pharyngitis and can also cause rheumatic fever and other potentially serious illnesses.
See the full article here.
Go to kBLASTER to FDA 510(k) search for a primary predicate, multiple predicates or reference devices, and harness kBLASTER's uniquely effective result management features, so you can quickly build a successful 510(k) clearance strategy.
